Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance Therapy in DLBCL
ChiCTR2600122572Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: 3-year progression-free survival rate. Started Apr 2026; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600122572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122572.